TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
ID：am030003M0034560wczt8📫 -页
内容摘要
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
海外数据平台所有内容均是公开网络、AI代理代查、客户上传分享、合作方，仅供网友学习交流，请勿商用!
